Canalevia®-CA1 is currently FDA conditionally approved for treatment of CID in dogs and is the first and only treatment for…
RESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will…
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ETSOUTH SAN FRANCISCO, Calif., July 26, 2023 (GLOBE NEWSWIRE) --…
BERKELEY HEIGHTS, N.J., July 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and…
BOCA RATON, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in…
LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies,…
ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy End-of-Phase 2 meeting with FDA…
Cell therapy CDMO spins out of Inceptor Bio to help innovators develop and manufacture life-saving cell therapies Kincell to be…
HOUSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation…
Acquisition will accelerate global commercial expansion of the company’s product portfolio, including Barrigel® SANTA BARBARA, Calif. and STOCKHOLM, Sweden, July…